Followers | 134 |
Posts | 7040 |
Boards Moderated | 0 |
Alias Born | 02/09/2012 |
![](https://investorshub.advfn.com/uicon/323933.png?cb=1618788139)
Thursday, December 24, 2020 2:03:16 PM
YOU also need to know that the BODY of Scientific Test results and former Clinical Trials...have demonstrated POSITIVE SUCCESS AND EFFICACY each time...
FACT: Brilacidin has NEVER FAILED in any of the 8 HUMAN Clinical Trials (in other indications) and has consistently demonstrated in U.S. Regional Bio-containment Laboratories the HIGHEST TEST RESULTS in reducing Covid-19 VIRAL LOAD of any Therapeutic Candidate.
FACT: No IPIX detractor can refute the enormous prospective results expected from BRILACIDIN based on the science... (they trash the CEO, Leo...who got us here...
FACT: THE REST IS BULL SH*T!
Funding for trials have been raised...and IPIX is full steam ahead. IMO trials results...will result in huge $ coming into IPIX to fund manufacturing of product etc...IF, of course, IPIX is not acquired by BP before hand.
KNOW WHAT YOUR OWN...do the DD reading...and listen to Farrell and others who understand the truth of the enormous upside potential of Brilacidin and IPIX.
From Farrell:
I am looking forward to the coming year. New investors need to read the PR's from the initial 2/18/2020 announcement of Brilacidin for Covid 19 to the announcement of human clinical trials on 12/21/2020.
What they will find is a logical progression of basic scientific research where each success is built upon leading to additional study and success until the clinical trial announcement. In vitro testing conclusively demonstrates Brilacidin is one of the most promising therapeutics for Covid 19. This body of work is leading to human clinical trials where Brilacidin will be given to humans sick with Covid 19. It is a remarkable achievement for such a small company
www.ipharminc.com/press-release
-2/18 Initial announcement of Brilacidin for Covid 19
-2/24 Material transfer agreements to virology labs
-2/28 Brilacidin sent to Regional Biodefense Labs {RBL)for study
-3/2 Brilacidin PDF outlines scientific rationale for use against Covid19
-3/9 Brilacidin studies planned at RBL
-3/12 Testing to begin 3/16
-4/1 Brilacidin effective against Covid19 in Vero monkey cells
-4/6 Early discussions of human trials
-4/20 Screening of 11,552 compounds shows Brilacidin a leading drug against Covid19 by inhibiting the M-protease
-4/27 Initial research confirms anti Covid properties more research planned
-5/5 PHRI studies announced
-5/19 Brilacidin reduces Covid 75% in preincubtion Vero cell study
-5/26 Brilacidin reduces Covid in human renal cell line; blocks viral cell entry
-6/11 Brilacidin study to include MERS and SARS pan corona virus testing; Grant application application made
-6/17 Brilacidin inhibits Covid 97% in infected Human respiratory cells
-7/7 Brilacidin active against Covid 19 before during and after Covid infects cells
-7/13 Human clinical trial planning/manufacture of Brilacidin announced
-7/20 Brilacidin at low dosage is effective against Covid19; lower than ABSSI dose
-8/4 Brilacidin shown effective against entire Covid life cycle
-8/24 Brilacidin Selectivity index among highest reported
-8/26 Dr Degrado announced as science advisor
-9/15 Brilacidin synergistic with remdesivir;reduces viral load almost 100%
-10/2 Pre IND meeting; Brilacidin human clinical trials
-10/30 RBL preprint article released; Selectivity index 426 one of highest achieved
-11/2 FDA pre IND response received;CRO secured
-11/16 Overseas CTA submitted;Brilacidin viral resistance unlikely
-11/30 New research for Brilacidin as a pancoronavirus treatment
FDA application submitted
-12/21 Brilacidin for phase 2 Covid study approved
Where some see lies and deceit, I see scientific advancement,diligence and competence resulting in success.
Good luck to all,
Farrell
PS. COVID-19 about to get more aggressive...and pervasive.
https://www.theepochtimes.com/ccp-virus-variant-in-uk-spreads-over-50-percent-faster-study_3631533.html?utm_source=pushengage
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM